



MannKind Corporation to Participate in H.C. Wainwright Bioconnect Conference

01/05/22

DANBURY, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- **MannKind Corporation (Nasdaq: MNKD)**, a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer Michael Castagna, PharmD, will present at the H.C. Wainwright Bioconnect Conference which will be available on demand starting on January 10, 2022.

Interested parties can access a link to the on demand webcast of the presentation from the Events & Presentations section of the Company's website at <https://investors.mannkindcorp.com/events-and-presentations>. The webcast replay may be accessed at the same location for 14 days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. Afrezza is also available by prescription in Brazil, where it is commercialized by the Company's partner, Biomm SA. MannKind was established in 1991, and is located in Danbury, Conn., and Westlake Village, Calif. The Company also employs field sales and medical representatives across the U.S. Please visit mannkindcorp.com to learn more.

Contact:

Rose Alinaya, Investor Relations

(818) 661-5000

Email: ir@mannkindcorp.com



Source: MannKind